OR WAIT null SECS
A $100-million investment will expand a range of the CDMO’s service capabilities and offerings.
Ajinomoto Bio-Pharma Services, a provider of biopharmaceutical contract development and manufacturing, announced several expansions of its capabilities and service offerings in the United States and Belgium totaling more than $100 million, the company announced in a March 12, 2019 press release.
In addition to the previously announced highly potent product conjugation and fully isolated fill line, which has recently started operations in its new facility in San Diego, CA, the company is also adding a new fully isolated, nested flexible fill line, installing automated packaging and labeling equipment, and upgrading its continuous flow and small-molecule API manufacturing capabilities.
The company reports the following updates:
Source: Ajinomoto Bio-Pharma Services